Utility of Presepsin and Interferon-λ3 for Predicting Disease Severity and Clinical Outcomes in COVID-19 Patients
-
Published:2023-07-14
Issue:14
Volume:13
Page:2372
-
ISSN:2075-4418
-
Container-title:Diagnostics
-
language:en
-
Short-container-title:Diagnostics
Author:
Lee Gun-Hyuk1ORCID, Park Mikyoung2ORCID, Hur Mina1ORCID, Kim Hanah1ORCID, Lee Seungho3ORCID, Moon Hee-Won1ORCID, Yun Yeo-Min1ORCID
Affiliation:
1. Department of Laboratory Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, 120-1, Neungdong-ro, Hwayang-dong, Gwangjin-gu, Seoul 05030, Republic of Korea 2. Department of Laboratory Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of Korea 3. Department of Preventive Medicine, College of Medicine, Dong-A University, Busan 49201, Republic of Korea
Abstract
We explored the utility of novel biomarkers, presepsin and interferon-λ3 (IFN-λ3), for predicting disease severity and clinical outcomes in hospitalized Coronavirus (COVID-19) patients. In a total of 55 patients (non-critical, n = 16; critical, n = 39), presepsin and IFN-λ3 were compared with sequential organ failure assessment (SOFA) scores and age. Disease severity and clinical outcomes (in-hospital mortality, intensive care unit admission, ventilator use, and kidney replacement therapy) were analyzed using receiver operating characteristic (ROC) curves. In-hospital mortality was also analyzed using the Kaplan-Meier method with hazard ratios (HR). SOFA scores, age, presepsin, and IFN-λ3 predicted disease severity comparably (area under the curve [AUC], 0.67–0.73). SOFA score and IFN-λ3 predicted clinical outcomes comparably (AUC, 0.68–0.88 and 0.66–0.74, respectively). Presepsin predicted in-hospital mortality (AUC = 0.74). The combination of presepsin and IFN-λ3 showed a higher mortality risk than SOFA score or age (HR [95% confidence interval, CI], 6.7 [1.8–24.1]; 3.6 [1.1–12.1]; 2.8 [0.8–9.6], respectively) and mortality rate further increased when presepsin and IFN-λ3 were added to SOFA scores or age (8.5 [6.8–24.6], 4.2 [0.9–20.6], respectively). In the elderly (≥65 years), in-hospital mortality rate was significantly higher when both presepsin and IFN-λ3 levels increased than when either one or no biomarker level increased (88.9% vs. 14.3%, p < 0.001). Presepsin and IFN-λ3 predicted disease severity and clinical outcomes in hospitalized COVID-19 patients. Both biomarkers, whether alone or added to the clinical assessment, could be useful for managing COVID-19 patients, especially the elderly.
Funder
Konkuk University Medical Center
Subject
Clinical Biochemistry
Reference35 articles.
1. World Health Organization (2023, May 10). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/table. 2. COVID-19 mortality in adults aged 65 and over: United States, 2020;Kramarow;NCHS Data Brief.,2022 3. Yanez, N.D., Weiss, N.S., Romand, J.-A., and Treggiari, M.M. (2020). COVID-19 mortality risk for older men and women. BMC Public Health, 20. 4. (2023, January 07). Word Health Organization: Living Guidance for Clinical Management of COVID-19. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. 5. Immune response and COVID-19: A mirror image of sepsis;Aguirre;Int. J. Biol. Sci.,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|